Article
Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2002
Johnson Martin R, Wang Kangsheng, Diasio Robert B
Abstract excerpt
A familial approach was used to elucidate the genetic determinants of profound and partial dihydropyrimidine dehydrogenase (DPD; EC 1.3.1.2) deficiency in an Alabama family. In 1988, our laboratory diagnosed profound DPD deficiency in a breast cancer patient with grade IV toxicity after cyclophosphamide/methotrexate/5-fluorouracil chemotherapy (R. B. Diasio et al., J. Clin. Investig., 81: 47-51, 1988). We now...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
